Tests Daoyin exercise technique to improve endurance in lung fibrosis
Tests a guided Daoyin exercise technique in adults with idiopathic pulmonary fibrosis.
Plain-language title generated from the registry record
Registry title: Daoyin Technique for Improving Exercise Endurance in IPF
Key facts
- Where
- Beijing, Shenyang, and Zhengzhou, ChinaSee the 3 sites
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 40 and 85 years old?
Source: NCT07019714, who can take part
Where in China
- Xiyuan Hospital of China Academy of Chinese Medical SciencesBeijing, ChinaTaking people
- The Affiliated Hospital of Liaoning University of Traditional Chinese Medicinenese MedicineShenyang, ChinaTaking people
- The First Affiliated Hospital of Henan University of Traditional Chinese MedicineZhengzhou, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Affiliated Hospital of Liaoning University of Traditional Chinese Medicine
- Trial code
- NCT07019714
- Record updated
- 29 September 2026
- Original description
This study is based on the previously constructed digital rehabilitation management platform, scientifically evaluating the clinical efficacy of guided technology in improving IPF exercise endurance, and forming high-quality clinical evidence.Read full original descriptionShow less
Clinical Research on the Improvement of Exercise Endurance in Idiopathic Pulmonary Fibrosis by Daoyin Technique
This study is based on the previously constructed digital rehabilitation management platform, scientifically evaluating the clinical efficacy of guided technology in improving IPF exercise endurance, and forming high-quality clinical evidence.
Inclusion: Patients who meet the diagnostic criteria for IPF; Those who can tolerate guided - technique training; Aged between 40 and 85 years old; Those who can independently or with the assistance of family members use devices such as smartphones and computers during home - based training; Those who voluntarily accept treatment and sign the informed consent form.
Exclusion: Patients who have been participating in other clinical trials within 1 month before enrollment; Patients with comorbidities such as chronic obstructive pulmonary disease, lung cancer, active pulmonary tuberculosis, bronchiectasis, pulmonary embolism, and other pulmonary diseases; Patients with severe cardiovascular and cerebrovascular diseases (malignant arrhythmia, unstable angina pectoris, acute myocardial infarction, cardiac function at grade 3 or above, stroke, cerebral hemorrhage, etc.); Patients with severe liver diseases (such as bleeding caused by liver cirrhosis, portal hypertension, and esophagogastric varices) and severe kidney diseases (dialysis, kidney transplantation, etc.); Patients with progressive neuromuscular diseases; Patients with unclear consciousness, dementia, and various mental illnesses; Patients in the acute exacerbation phase of IPF; Patients with severe osteoarthropathy or osteoporosis, and those with unstable fractures; Pregnant or lactating women, and patients with a recent pregnancy plan; Patients who need long - term use of ventilators and those with unstable vital signs while bedridden.